NewEdge Advisors’s PharmaCyte Biotech PMCB Stock Holding History

NewEdge Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2	Hold	2	–	–	﹤0.01%	4178
2026 Q1	$1	Hold	2	–	–	﹤0.01%	4124
2025 Q4	$1	Hold	2	–	–	﹤0.01%	4200
2025 Q3	$2	Hold	2	–	–	﹤0.01%	4089
2025 Q2	$2	Hold	2	–	–	﹤0.01%	3977
2025 Q1	$3	Hold	2	–	–	﹤0.01%	3932
2024 Q4	$3	Hold	2	–	–	﹤0.01%	3890
2024 Q3	$4	Hold	2	–	–	﹤0.01%	3795
2024 Q2	$4	Sell	2 -1	-33%	-$2	﹤0.01%	3771
2024 Q1	$7	Hold	3	–	–	﹤0.01%	3784
2023 Q4	$6	Hold	3	–	–	﹤0.01%	3721
2023 Q3	$6	Buy	3 +1	+50%	+$3	﹤0.01%	3443
2023 Q2	$6	Hold	2	–	–	﹤0.01%	3470
2023 Q1	$6	Hold	2	–	–	﹤0.01%	3401
2022 Q4	$0	Buy	+2	New	+$6	﹤0.01%	4176

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

NewEdge Advisors's PMCB Position: Q2 2026 in Review

NewEdge Advisors held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4178.

NewEdge Advisors first reported a position in PMCB in Q4 2022 and has held it in 15 quarters since. The position peaked at $7 in Q1 2024. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

NewEdge Advisors held 2 shares of PharmaCyte Biotech worth $2 as of Q2 2026.
NewEdge Advisors left its PharmaCyte Biotech share count unchanged in Q2 2026.
PharmaCyte Biotech made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #4178 holding.
NewEdge Advisors first reported a position in PharmaCyte Biotech in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's PharmaCyte Biotech position peaked at $7 in Q1 2024.
19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.